Cellular Biomedicine Group out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront, plus milestones. Also, Shanghai Laekna Therapeutics completed an IPO on the Hong Kong Exchange, raising $100 million.